Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir
In Vivo · 2025
DOI: 10.21873/invivo.14005 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Yuta Nakamaru und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan. Hauptthemen laut MEDLINE: Lopinavir, Ritonavir, COVID-19 Drug Treatment, Antiviral Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan.
- Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
- Department of Clinical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan; t-maeda@nichiyaku.ac.jp.
Zitieren
APA
Nakamaru, Y., Sako, K. I., Ide, N., Matsuda, Y., Yamashita, F., & Maeda, T. (2025). Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir. In Vivo. https://doi.org/10.21873/invivo.14005
Vancouver
Nakamaru Y, Sako KI, Ide N, Matsuda Y, Yamashita F, Maeda T. Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir. In Vivo. 2025. doi:10.21873/invivo.14005
BibTeX
@article{Nakamaru2025,
author = {Nakamaru, Yuta and Sako, Ken-Ichi and Ide, Naohito and Matsuda, Yoshikazu and Yamashita, Fumiyoshi and Maeda, Tomoji},
title = {Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.14005}
}
EUVIMED